Literature DB >> 15964500

Pharmacodynamics of tobramycin in patients with cystic fibrosis.

Johan W Mouton1, Nico Jacobs, Harm Tiddens, Alphonsus M Horrevorts.   

Abstract

Relationships between pharmacodynamic indices (PI), such as the area under the concentration-time curve (AUC)/MIC ratio and time > MIC (T(>MIC)), and efficacy have been described for antimicrobial drugs. The use of these quantitative relationships may increase the power to demonstrate significant effects of drugs, obviating the need to include large numbers in comparative trials. Patients with cystic fibrosis (CF) hospitalized for treatment of an infectious exacerbation due to Pseudomonas aeruginosa were eligible for the study. They received tobramycin 3.3 mg/kg tid as initial therapy in combination with ticarcillin 125 mg/kg qid. Blood samples were drawn at t = 0-8 h after infusion. Pharmocokinetic parameters and PI were calculated for every individual and correlated to the relative improvement in forced expiratory volume during the first second (FEV1) and forced vital capacity (FVC) between pretreatment and days 9-11 as a measure of efficacy. The 3 PI fAUC/MIC, f Peak/MIC, and T(>MIC) of tobramycin showed a significant correlation with effect and was the highest for the fAUC/MIC relationships with FEV1 and FVC as determined both by the Emax model as well as Spearman correlations (r = 0.77, P = 0.002 and 0.58, P = 0.036 for FEV1 and FVC). Pharmacokinetic parameters AUC and Peak as such showed no significant correlation with effect, nor did the MIC values. There is a significant relationship between PI of aminoglycosides and efficacy parameter (increase in FEV1 and FVC) in patients with CF. This study demonstrates the applicability of pharmacodynamic relationships in determining efficacy of antimicrobial therapy, by demonstrating a strong PI-effect relationship in a group of only 13 patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964500     DOI: 10.1016/j.diagmicrobio.2005.02.011

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  24 in total

1.  Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Wil H F Goessens; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.

Authors:  Christopher M Rubino; John S Bradley
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 3.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

4.  Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Samer Kabbara; Giao Vo; Amy N Schilling; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.

Authors:  Kevin J Downes; Min Dong; Tsuyoshi Fukuda; John P Clancy; Christopher Haffner; Michael R Bennett; Alexander A Vinks; Stuart L Goldstein
Journal:  J Antimicrob Chemother       Date:  2016-09-01       Impact factor: 5.790

6.  Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Reiko Sato; Yusuke Tanigawara; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

7.  Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients.

Authors:  Clément Boidin; Laurent Bourguignon; Sabine Cohen; Claire Roger; Jean-Yves Lefrant; Jason A Roberts; Bernard Allaouchiche; Alain Lepape; Arnaud Friggeri; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

8.  Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.

Authors:  Alexander A Vinks; Ronald N van Rossem; Ron A A Mathôt; Harry G M Heijerman; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?

Authors:  Yanhua Gao; Stefanie Hennig; Michael Barras
Journal:  Clin Pharmacokinet       Date:  2019-03       Impact factor: 6.447

10.  Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach.

Authors:  Jeffery T Zobell; Kevin Epps; Frederick Kittell; Clarissa Sema; Erin J McDade; Stacy J Peters; Mariela A Duval; Rebecca S Pettit
Journal:  J Pediatr Pharmacol Ther       Date:  2016 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.